ive attenuated viral vaccines are a part of routine childhood immunizations and over the years have proved their safety and efficacy in the general population. Mild adverse effects of measles-mumps-rubella (MMR) vaccination include fever, rash, and lymphadenopathy and occur in approximately 5% to 15% of vaccine recipients. 1,2 Similarly, side effects of the varicella vaccine include injection site reactions, fever, and rash, which occur in 5% to 30% of individuals. [3] [4] [5] Severe side effects are exceedingly rare with both vaccinations. 5, 6 The package inserts for both the varicella and MMR vaccines warn against use in patients with any form of cellular or humoral immunodeficiency. However, the most recent Advisory Committee on Immunization Practices allows the use of varicella vaccine in patients with a humoral immunodeficiency as well as in patients with human immunodeficiency virus with age-specific CD4 count Ն25%. 4 No published guidelines exist for the administration of these vaccines to patients with chromosome 22q11.2 deletion syndrome. 7 This syndrome is associated with thymic hypoplasia and diminished T-cell numbers and has a wide spectrum of phenotypic features that include cardiac anomalies, dysmorphic facial features, and hypocalcemia. 8, 9 Patients gener-
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METHODS
A total of 174 patients who had a genetically confirmed diagnosis of chromosome 22q11.2 deletion and were seen at Children's Hospital of Philadelphia between 1994 and 2002 constituted the study population. A retrospective analysis of vaccine adverse events was performed. Institutional review board approval was granted for this study.
The data acquisition form was designed to evaluate the frequency of live vaccine administration and the consequences of both vaccination and withholding the vaccine. Many of the patients received the vaccine before the diagnosis of chromosome 22q11.2 deletion syndrome. Flow cytometric enumeration of T cells was performed in the Clinical Immunology Laboratory of the Children's Hospital of Philadelphia using standard techniques as part of an immunologic evaluation.
RESULTS
Fifty-nine responses were received from 174 directed mailings. T-cell numbers from survey responders were no different from T-cell numbers from people who enrolled in the cohort but failed to respond to the survey (CD3: 1759 vs 1669 cells/L; CD4: 1142 vs 1076 cells/L; CD8: 489 vs 503 cells/ L). Thirty-two of 59 responders were vaccinated with the varicella vaccine. Only 9% of patients reported adverse events (Table 1) . However, 63% of unvaccinated children developed chickenpox. Comparison of patients who tolerated the vaccine with those who reported adverse events showed no statistically significant differences in current age (7 vs 5.7 years), age at vaccination (3 vs 2. Fifty-two of 59 responders were vaccinated with MMR. Twelve (23%) of 52 reported mild side effects, including fever, rash, and constitutional symptoms (Table 1) . No severe adverse reactions were reported. No patient (vaccinated or unvaccinated) reported natural disease with measles, mumps, or rubella. There were no statistically significant differences between the T-cell counts in the vaccinated group reporting side effects versus the vaccinated group without side effects (mean CD3 counts: 1928 vs 1736 cells/L, P ϭ .795; CD4 counts 1250 vs 1127 cells/ L, P ϭ .863; and CD8 counts 528 vs 483 cells/L, P ϭ .798; Fig 1) . Comparison of vaccinated and unvaccinated groups showed significant differences only for age at time of study (8.9 vs 6 years; P ϭ .04). Comparison of vaccinated and unvaccinated patients showed no significant differences in CD3 counts (1759 vs 1315 cells/L; P ϭ .14), CD4 counts (1142 vs 914 cells/L; P ϭ .22), and CD8 counts (489 vs 340 cells /L; P ϭ .15).
Unfortunately, low T-cell counts were not an indicator of adverse events. We also examined whether poor response to phytohemagglutinin was associated with adverse reactions to immunizations. MMR recipients who did not have an adverse reaction had a mean stimulation index of 383 Ϯ 335, whereas those who had adverse reactions had a mean stimulation index of 381 Ϯ 343 (P ϭ .99). Similarly, there were no significant differences between varicella immunization recipients with and without adverse reactions (430 vs 360; P ϭ .36).
DISCUSSION
In our study, patients with chromosome 22q11.2 deletion syndrome had a similar incidence of adverse effects with varicella and MMR vaccines compared with that reported in the general population. Nine percent of patients who received the varicella vaccine reported side effects compared with 5% to 30% in the general population. Twenty-three percent of patients who received the MMR vaccine reported side effects compared with 5% to 15% in the general population. All side effects were mild. However, in patients who did not receive the varicella vaccine, an overwhelming 63% contracted the disease. Patients who were not vaccinated against MMR did not develop natural disease. The discrepancy between the 2 groups of unvaccinated patients is probably attributable to differences in the prevalence of these diseases in the United States.
The data suggest that this is a cohort of patients with 22q11.2 deletion syndrome who have tolerated live viral vaccinations without evidence of significant side effects. Study limitations include the use of published comparative data, a limited number of participants, and a retrospective design that relies on parental recollection. In addition, T-cell counts were not available for every patient at the time immediately preceding vaccination; therefore, counts closest to vaccination were used. For the MMR group, the average difference between the age at which cell counts were obtained and the vaccine was administered was 55 months. For the varicella vaccine group, the mean difference in age between vaccination and the age at which the T-cell studies were obtained was 19.3 months.
A prospective study could address whether there are T-cell thresholds below which vaccination is unsafe; however, the information that we present suggests that vaccinating children with chromosome 22q11.2 deletion with live viral vaccines does not carry a significantly higher risk of adverse reactions compared with the general population, provided that they have no evidence of severe immunocompromise. On the contrary, withholding vaccination, especially in the case of more prevalent infections such as varicella, can result in a high frequency of wild-type disease. Prospective studies to confirm the findings presented here are necessary to be able to guide families and caregivers in the risk-benefit analysis of live viral vaccine administration.
